Results 101 to 110 of about 293,395 (315)
Cyclic adenosine 5'-monophosphate in Escherichia coli [PDF]
, 1976 Ira Pastan, Sankar Adhya
openalex +1 more source
ADENOSINE TRIPHOSPHATE-ADENOSINE MONOPHOSPHATE TRANSPHOSPHORYLASE
Journal of Biological Chemistry, 1958 openaire +3 more sources
Somatic cell reprogramming for Parkinson's disease treatment
Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley +1 more source
Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle. [PDF]
, 1978 J G Dobson
openalex +1 more source
Function of the master energy regulator adenosine monophosphate‐activated protein kinase in stroke
Journal of Neuroscience Research, 2013 B. Manwani, L. McCullough
semanticscholar +1 more source
The mechanisms in glucose metabolism of aging hippocampus
Ibrain, EarlyView.Cognitive decline in elders stems from the irreversible loss and functional decline of neurons, with the hippocampus being particularly susceptible to age‐related neuronal deterioration. Glucose acts as the primary fuel for the brain, and a constant provision of glucose to the hippocampus is essential for memory and cognitive functions.
Rui He +6 more
wiley +1 more source
Downregulation of cyclic adenosine monophosphate levels in leukocytes of hibernating captive black bears is similar to reported cyclic adenosine monophosphate findings in major depressive disorder. [PDF]
Front Psychiatry, 2023 Tsiouris JA, Flory M.
europepmc +1 more source
International Journal of Cancer, EarlyView.Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao +6 more
wiley +1 more source